<p>/PRNewswire/ -- Schall 律师事务所是一家全国性的股东权益诉讼事务所，提醒投资者注意针对 Capricor Therapeutics, Inc.（&#34;Capricor&#34;或&#34;公司&#34;）（NASDAQ: CAPR）的集体诉讼，因其违反了 1934 年证券交易法第 10(b) 和 20(a) 条款以及美国证券交易委员会制定的第 10b-5 条规则。</p>
<p>在 2024 年 10 月 9 日至 2025 年 7 月 10 日（包括该日期）期间购买公司证券的投资者，鼓励在 2025 年 9 月 15 日之前与本事务所联系。</p>
<p>如果您是遭受损失的股东，请点击此处参与。</p>
<p>我们还鼓励您联系 Schall 律师事务所的 Brian Schall，地址为 2049 Century Park East, Suite 2460, Los Angeles, CA 90067，电话 310-301-3335，免费讨论您的权利。您也可以通过事务所的网站 www.schallfirm.com 或电子邮件 [email protected] 与我们联系。</p>
<p>本案的集体诉讼尚未获得认证，在认证之前，您并未由律师代表。如果您选择不采取任何行动，您可以保持缺席集体成员身份。</p>
<p>根据投诉，公司向市场发布了虚假和误导性声明。Capricor 吹嘘其在 FDA 批准其 deramiocel 药物候选者方面取得的成功进展，例如中期审查没有重大缺陷以及计划召开顾问委员会会议。尽管如此，公司却隐瞒了来自第二阶段 HOPE-2 试验的不利数据。基于这些事实，公司在整个集体诉讼期间的公开声明都是虚假和具有实质性误导性的。当市场了解到 Capricor 的真相时，投资者遭受了损失。</p>
<p>加入本案以追回您的损失。</p>
<p>Schall 律师事务所代表全球投资者，专注于证券集体诉讼和股东权益诉讼。</p>
<p>根据适用法律和伦理规则，本新闻稿在某些司法管辖区可能被视为律师广告。</p>
<p><strong>联系方式：</strong></p>
<p>Schall 律师事务所</p>
<p>Brian Schall, Esq.,</p>
<p>www.schallfirm.com</p>
<p>办公室：310-301-3335</p>
<p>[email protected]</p>
<p>来源：Schall 律师事务所</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNzI4Jk5ld3NJdGVtSWQ9TEEzODQwOSZUcmFuc21pc3Npb25fSWQ9MjAyNTA3MjgxMDQ4UFJfTkVXU19VU1BSX19fX19MQTM4NDA5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNzI4Jk5ld3NJdGVtSWQ9TEEzODQwOSZUcmFuc21pc3Npb25fSWQ9MjAyNTA3MjgxMDQ4UFJfTkVXU19VU1BSX19fX19MQTM4NDA5"/></p>

Capricor治疗

<p>Schall 律师事务所提醒投资者，针对 Capricor Therapeutics, Inc.的证券欺诈行为提起了集体诉讼。诉讼声称 Capricor 对其药物候选者 deramiocel 做出了虚假陈述，同时隐瞒了临床试验中的负面数据。鼓励在 2024 年 10 月 9 日至 2025 年 7 月 10 日期间购买证券的投资者在 2025 年 9 月 15 日之前联系该事务所，以讨论他们的权利和可能参与诉讼的机会</p>

<p>, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. (&#34;Capricor&#34; or &#34;the Company&#34;) (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Schall 律师事务所是一家全国性的股东权益诉讼事务所，提醒投资者注意针对 Capricor Therapeutics, Inc.（&#34;Capricor&#34;或&#34;公司&#34;）（NASDAQ: CAPR）的集体诉讼，因其违反了 1934 年证券交易法第 10(b) 和 20(a) 条款以及美国证券交易委员会制定的第 10b-5 条规则。</p>
</div><p>Investors who purchased the Company's securities between October 9, 2024, and July 10, 2025, inclusive (the &#34;Class Period&#34;), are encouraged to contact the firm before September 15, 2025.</p>
<div class="lb-trans"><p>在 2024 年 10 月 9 日至 2025 年 7 月 10 日（包括该日期）期间购买公司证券的投资者，鼓励在 2025 年 9 月 15 日之前与本事务所联系。</p>
</div><p>If you are a shareholder who suffered a loss, click here to participate.</p>
<div class="lb-trans"><p>如果您是遭受损失的股东，请点击此处参与。</p>
</div><p>We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].</p>
<div class="lb-trans"><p>我们还鼓励您联系 Schall 律师事务所的 Brian Schall，地址为 2049 Century Park East, Suite 2460, Los Angeles, CA 90067，电话 310-301-3335，免费讨论您的权利。您也可以通过事务所的网站 www.schallfirm.com 或电子邮件 [email protected] 与我们联系。</p>
</div><p>The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.</p>
<div class="lb-trans"><p>本案的集体诉讼尚未获得认证，在认证之前，您并未由律师代表。如果您选择不采取任何行动，您可以保持缺席集体成员身份。</p>
</div><p>According to the Complaint, the Company made false and misleading statements to the market. Capricor touted its successful movement towards FDA approval for its deramiocel drug candidate, such as a mid-cycle review with no important deficiencies and the planning of an advisory committee meeting. Despite this positivity, the Company was concealing adverse data from the Phase 2 HOPE-2 trial. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Capricor, investors suffered damages.</p>
<div class="lb-trans"><p>根据投诉，公司向市场发布了虚假和误导性声明。Capricor 吹嘘其在 FDA 批准其 deramiocel 药物候选者方面取得的成功进展，例如中期审查没有重大缺陷以及计划召开顾问委员会会议。尽管如此，公司却隐瞒了来自第二阶段 HOPE-2 试验的不利数据。基于这些事实，公司在整个集体诉讼期间的公开声明都是虚假和具有实质性误导性的。当市场了解到 Capricor 的真相时，投资者遭受了损失。</p>
</div><p>Join the case to recover your losses.</p>
<div class="lb-trans"><p>加入本案以追回您的损失。</p>
</div><p>The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.</p>
<div class="lb-trans"><p>Schall 律师事务所代表全球投资者，专注于证券集体诉讼和股东权益诉讼。</p>
</div><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.</p>
<div class="lb-trans"><p>根据适用法律和伦理规则，本新闻稿在某些司法管辖区可能被视为律师广告。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>The Schall Law Firm</p>
<div class="lb-trans"><p>Schall 律师事务所</p>
</div><p>Brian Schall, Esq.,</p>
<div class="lb-trans"><p>Brian Schall, Esq.,</p>
</div><p>www.schallfirm.com</p>
<div class="lb-trans"><p>www.schallfirm.com</p>
</div><p>Office: 310-301-3335</p>
<div class="lb-trans"><p>办公室：310-301-3335</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>SOURCE The Schall Law Firm</p>
<div class="lb-trans"><p>来源：Schall 律师事务所</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNzI4Jk5ld3NJdGVtSWQ9TEEzODQwOSZUcmFuc21pc3Npb25fSWQ9MjAyNTA3MjgxMDQ4UFJfTkVXU19VU1BSX19fX19MQTM4NDA5" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA38409&amp;Transmission_Id=202507281048PR_NEWS_USPR_____LA38409&amp;DateId=20250728"/></p>

CAPR 投资者有机会与 Schall 律师事务所合作，领导针对 Capricor 治疗公司的证券欺诈诉讼